Details for New Drug Application (NDA): 021222
✉ Email this page to a colleague
The generic ingredient in SPECTRACEF is cefditoren pivoxil. There are six drug master file entries for this compound. Additional details are available on the cefditoren pivoxil profile page.
Summary for 021222
| Tradename: | SPECTRACEF |
| Applicant: | Vansen Pharma |
| Ingredient: | cefditoren pivoxil |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Aug 29, 2001 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 400MG | ||||
| Approval Date: | Jul 21, 2008 | TE: | RLD: | No | |||||
Expired US Patents for NDA 021222
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vansen Pharma | SPECTRACEF | cefditoren pivoxil | TABLET;ORAL | 021222-002 | Jul 21, 2008 | 4,839,350 | ⤷ Start Trial |
| Vansen Pharma | SPECTRACEF | cefditoren pivoxil | TABLET;ORAL | 021222-001 | Aug 29, 2001 | 4,839,350 | ⤷ Start Trial |
| Vansen Pharma | SPECTRACEF | cefditoren pivoxil | TABLET;ORAL | 021222-002 | Jul 21, 2008 | 5,958,915 | ⤷ Start Trial |
| Vansen Pharma | SPECTRACEF | cefditoren pivoxil | TABLET;ORAL | 021222-001 | Aug 29, 2001 | 5,958,915 | ⤷ Start Trial |
| Vansen Pharma | SPECTRACEF | cefditoren pivoxil | TABLET;ORAL | 021222-001 | Aug 29, 2001 | 4,918,068 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
